Standard immunotherapies have transformed melanoma outcomes, but many patients remain resistant or relapse after treatment. This project is focused on developing personalised therapies, including mRNA cancer vaccines, to better target each patient’s tumour. By integrating multi-omic approaches such as genomics, immunopeptidomics, and functional immune assays, we aim to identify the most relevant tumour antigens and design vaccines tailored to each patient. We are also exploring the optimal timing of these therapies, in neoadjuvant, adjuvant, and metastatic settings, to enhance immune priming and improve long-term survival. Ultimately, this work seeks to bring truly individualised treatment options into the clinic for patients with high-risk or therapy-resistant melanoma.